Low Blood Sugar on Insulin: Drugs That Cause or Treat It

Why Insulin Causes Low Blood Sugar

Insulin lowers blood glucose by driving sugar from the bloodstream into cells. When the dose overshoots what the body needs at a given moment, glucose drops below the 70 mg/dL threshold the American Diabetes Association defines as hypoglycemia [1]. This mismatch happens more often than most patients expect.

The Mismatch Between Injected and Endogenous Insulin

A healthy pancreas fine-tunes insulin output minute by minute in response to food, activity, and stress hormones. Injected insulin cannot replicate this feedback loop. Once subcutaneous insulin absorbs into the bloodstream, it acts on a fixed pharmacokinetic curve regardless of what the body actually needs. A 2020 analysis in Diabetes Care found that among insulin-treated adults with type 2 diabetes, self-reported hypoglycemia occurred in 23% of patients over a four-week period, while continuous glucose monitoring (CGM) data captured events in nearly twice that proportion [2].

Which Insulin Types Carry the Highest Risk

Not all insulins are equal for hypoglycemia. Rapid-acting analogs (lispro, aspart, glulisine) cause the sharpest glucose drops and are responsible for a large share of prandial hypoglycemia events, especially when meal timing shifts. Older basal insulins like NPH carry significant nocturnal hypoglycemia risk because of a pronounced peak 4 to 8 hours after injection. The SWITCH 2 trial (N=721) demonstrated that insulin degludec reduced confirmed hypoglycemia by 30% compared to glargine U-100 in type 2 diabetes, with nocturnal episodes dropping by 42% [3]. Premixed insulin formulations also present higher risk, because patients cannot adjust the basal and bolus components independently.

The ADA's 2025 Standards of Care state: "For patients with type 2 diabetes with high hypoglycemia risk, second-generation basal insulin analogs (U-300 glargine or degludec) are preferred over first-generation analogs or NPH" [1].

Other Drugs That Increase Hypoglycemia Risk on Insulin

Insulin alone accounts for a large portion of hypoglycemia-related emergency visits, but concomitant medications can push glucose even lower. The FDA Adverse Event Reporting System links insulin combined with sulfonylureas to the highest rate of severe hypoglycemia reports among all diabetes drug pairings [4].

Sulfonylureas and Meglitinides

Sulfonylureas (glipizide, glimepiride, glyburide) stimulate the pancreas to release insulin regardless of blood glucose levels. Adding a sulfonylurea to an insulin regimen effectively double-doses insulin secretion and delivery. Glyburide is the worst offender: its long duration of action (up to 24 hours) and active metabolites make hypoglycemia risk two to three times higher than with glimepiride [5]. Meglitinides (repaglinide, nateglinide) act by the same mechanism but clear faster, reducing but not eliminating the added risk. The Endocrine Society's 2023 clinical practice guideline recommends: "Sulfonylureas should generally be discontinued or substantially reduced when basal insulin is initiated" [6].

Less Obvious Offenders

Several non-diabetes medications can amplify insulin-induced hypoglycemia through distinct mechanisms:

• Beta-blockers (propranolol, atenolol, metoprolol): block the adrenergic symptoms (tremor, palpitations, sweating) that warn patients their glucose is dropping. They also impair hepatic glucose output. A retrospective cohort study of 12,803 insulin-treated patients found that non-selective beta-blockers increased severe hypoglycemia risk by 41% compared to no beta-blocker use [7].
• ACE inhibitors: may improve insulin sensitivity, occasionally dropping glucose further than expected. The effect is modest but clinically relevant in patients already titrated to tight glycemic targets.
• Fluoroquinolone antibiotics (levofloxacin, ciprofloxacin): directly stimulate pancreatic beta cells, producing hypoglycemia even in non-diabetic individuals. Risk rises substantially when layered on top of insulin [8].
• Quinine and hydroxychloroquine: stimulate insulin secretion independent of glucose levels.
• Alcohol: suppresses hepatic gluconeogenesis for 12 to 24 hours after consumption, creating a delayed hypoglycemia window that catches many patients off guard.

Recognizing Hypoglycemia Symptoms

Early recognition is the single best defense against a severe episode. Symptoms track along a predictable glucose gradient, though individual thresholds vary based on glycemic history and autonomic function.

Mild to Moderate Signs (Glucose 54 to 70 mg/dL)

Adrenergic (autonomic) symptoms appear first in most patients: shakiness, sweating, hunger, anxiety, and heart pounding. These are the body's counter-regulatory alarm system. Neuroglycopenic symptoms follow as glucose falls further: difficulty concentrating, blurred vision, slurred speech, and irritability. A key clinical point is that patients with recurrent hypoglycemia develop hypoglycemia unawareness, a condition where the autonomic warning threshold shifts downward. The HAAF (Hypoglycemia-Associated Autonomic Failure) phenomenon affects an estimated 25% of patients with type 1 diabetes and 10% of insulin-treated type 2 patients [9].

Severe Hypoglycemia (Glucose <54 mg/dL)

The ADA defines severe hypoglycemia as any event requiring another person's assistance, regardless of the measured glucose value [1]. Seizure, loss of consciousness, and confusion severe enough to prevent self-treatment all qualify. The Diabetes Control and Complications Trial (DCCT) recorded severe hypoglycemia in 65 per 100 patient-years in the intensive therapy group, a rate that underscores how common these events are when glucose targets are aggressive [10]. Severe hypoglycemia carries independent cardiovascular risk: the ACCORD trial (N=10,251) linked symptomatic severe hypoglycemia to a 2.87-fold increase in cardiovascular mortality [11].

Treating an Acute Hypoglycemic Episode

Speed matters. Brain tissue has no glucose reserves and depends entirely on circulating blood sugar. Treatment protocols are straightforward but must be followed precisely.

The Rule of 15

For any conscious patient with glucose <70 mg/dL:

1. Consume 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or 1 tablespoon of honey).
2. Wait 15 minutes.
3. Recheck blood glucose.
4. If still <70 mg/dL, repeat the 15 g dose.
5. Once glucose normalizes, eat a mixed meal or snack containing protein and complex carbohydrate to prevent recurrence [1].

Overtreating with large amounts of food is a common mistake. It causes rebound hyperglycemia and makes the next 24 hours of glucose management harder.

Glucagon for Severe Episodes

When a patient cannot swallow safely or is unconscious, glucagon is the rescue drug. Three FDA-approved formulations are now available:

• Glucagon injection kit (Eli Lilly): 1 mg intramuscular, requires reconstitution before injection.
• Baqsimi (nasal glucagon): 3 mg single-use nasal spray, no reconstitution needed [12].
• Gvoke (dasiglucagon): 0.5 mg or 1 mg prefilled autoinjector or syringe, ready to use [13].

Baqsimi and Gvoke have simplified severe hypoglycemia treatment for caregivers. A 2019 study in Diabetes Care showed that untrained caregivers administered nasal glucagon successfully in 94% of simulated emergencies compared to 13% success with the traditional injection kit [14]. Every insulin-treated patient should have a glucagon product prescribed, and household members should know where it is stored and how to use it.

Drugs and Strategies That Reduce Hypoglycemia Risk

Preventing hypoglycemia is not about relaxing glucose targets. It is about using the right tools to achieve those targets safely.

Switching to Safer Insulin Analogs

The biggest pharmacologic lever is the insulin itself. Two second-generation basal analogs have reshaped hypoglycemia profiles:

• Insulin degludec (Tresiba): ultra-long duration (>42 hours) with a flat, peakless profile. The DEVOTE trial (N=7,637) showed equivalent cardiovascular safety to glargine U-100 with 40% less severe hypoglycemia in a prespecified analysis [15].
• Insulin glargine U-300 (Toujeo): concentrated formulation that produces a more gradual, extended absorption profile than U-100 glargine. The EDITION trials showed 25 to 31% reduction in nocturnal hypoglycemia vs. Glargine U-100 [16].

For prandial coverage, ultra-rapid-acting insulins (Fiasp, Lyumjev) allow dosing at or just after the start of a meal, reducing the window where insulin activity exceeds carbohydrate absorption.

Continuous Glucose Monitoring

CGM has changed the risk equation for insulin-treated patients. Real-time CGM devices (Dexcom G7, Libre 3) provide predictive alerts that warn patients 10 to 30 minutes before glucose drops below a set threshold. The IMPACT trial (N=241) demonstrated that Libre CGM reduced time spent in hypoglycemia (<70 mg/dL) by 38% in type 1 diabetes patients with hypoglycemia unawareness [17]. Automated insulin delivery ("closed-loop") systems that pair CGM with an insulin pump go further, suspending basal delivery when glucose trends downward.

Adjunctive Medications That Lower Insulin Dose Requirements

Certain add-on drugs reduce the total daily insulin dose, which mechanically lowers hypoglycemia exposure:

• Metformin: remains first-line in type 2 diabetes and reduces insulin dose requirements by 15 to 25% without independently causing hypoglycemia [18].
• SGLT2 inhibitors (empagliflozin, dapagliflozin): produce insulin-independent glucose lowering through renal excretion. Adding an SGLT2 inhibitor to insulin typically allows a 10 to 20% basal insulin dose reduction. The risk of euglycemic ketoacidosis requires monitoring, particularly in type 1 patients [19].
• GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide): stimulate glucose-dependent insulin secretion, meaning they boost endogenous insulin only when glucose is elevated. The SUSTAIN 5 trial (N=397) showed that adding semaglutide to basal insulin reduced HbA1c by 1.4% while the rate of confirmed hypoglycemia remained below 2% [20].

When to Adjust Your Insulin Regimen

Not every low reading means the regimen is wrong, but patterns of hypoglycemia always demand a response. The ADA recommends a structured review at every clinical visit [1].

Identifying Patterns

Two weeks of glucose data (fingerstick log or CGM download) reveal whether hypoglycemia clusters at a specific time. Nocturnal lows between 2:00 and 4:00 AM point to excessive basal insulin. Post-exercise lows within 4 to 6 hours of activity suggest the need for a temporary basal rate reduction or pre-exercise snack. Postprandial lows 3 to 5 hours after a meal indicate the bolus dose may be too high or the insulin-to-carb ratio too aggressive.

Practical Dose Adjustments

For recurrent nocturnal hypoglycemia on NPH, switching to a peakless basal analog (degludec or glargine U-300) is the highest-yield change. For daytime lows on a basal-bolus regimen, reduce the responsible bolus dose by 10 to 20% and reassess after three days [6]. Patients experiencing hypoglycemia unawareness should have their glucose target temporarily raised to >100 mg/dL for 2 to 3 weeks to allow counter-regulatory hormone responses to recover, a strategy supported by the work of Philip Cryer at Washington University [9].

Special Populations

Older adults (age 65+) face disproportionate harm from hypoglycemia, including falls, fractures, and cognitive decline. The ADA assigns a less stringent HbA1c target (<8.0% or even <8.5%) for older adults with multiple comorbidities or limited life expectancy [1]. Renal impairment slows insulin clearance, extending its duration of action and raising hypoglycemia risk. Insulin doses often need reduction by 25 to 50% when eGFR falls below 30 mL/min/1.73 m² [6].

Patients taking corticosteroids experience predictable glucose spikes during steroid activity hours followed by drops when the steroid wears off. This pattern requires a corresponding insulin schedule, not a flat dose increase across 24 hours.